Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of$ 0.37 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 127.03%. A quarter ago, it was expected that this drug developer would post earnings of$ 0.28 per share when it actually produced earnings of $0.17, delivering a surprise of -39.29%. Over the last four quarters, the compa ...